Navigating 4 Analyst Ratings For Evolent Health
Portfolio Pulse from Benzinga Insights
Analysts have recently updated their ratings and price targets for Evolent Health (NYSE:EVH), showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target is now $45.0, down from $45.67. Actions include lowering and raising price targets by analysts from JP Morgan, Oppenheimer, JMP Securities, and Canaccord Genuity. Evolent Health's financial performance is strong, with notable revenue growth, net margin, ROE, ROA, and a healthy debt-to-equity ratio.
March 15, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evolent Health's ratings and price targets have been updated by analysts, showing a mix of bullish sentiments. Financial indicators like revenue growth and net margin are strong, suggesting a positive outlook.
The mix of bullish and somewhat bullish sentiments from analysts, combined with strong financial performance indicators such as revenue growth and net margin, suggest a positive short-term impact on EVH's stock price. The slight decrease in the average price target may temper expectations slightly, but the overall positive outlook from analysts and strong financial health of the company support a likely increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100